Drug Trial Radar · NCT07499362
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 26, 2026
Primary completion
Aug 22, 2028
Study completion Aug 22, 2028
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
Conditions
- Tenosynovial Giant Cell Tumor
Interventions
PimicotinibDrug
In the Safety Run-in Cohort, participants will receive 50 milligrams (mg) of pimicotinib once daily (QD), orally in 28-day cycles until disease progression (DP), death, discontinuation, or any other reason. The Safety Monitoring Committee (SMC) will monitor and assess tolerability of pimicotinib 50 mg QD during the safety run-in cohort. After making a recommendation about opening the Expansion Cohort based on the assessment in safety run-in cohort, participants will receive 50 mg of pimicotinib monotherapy QD, orally in 28-day cycles until disease progression (DP), death, discontinuation, or any other reason.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Run-In Cohort: Number of Participants with Dose Limiting Toxicity (DLT)-like eventsTime frame: Day 1 up to Day 28 of Cycle 1 (each cycle is of 28 days)
- Safety Run-In Cohort: Pharmacokinetic (PK) Plasma Concentration of PimicotinibTime frame: Pre-dose up to 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is of 28 days)
- Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review CommitteeTime frame: Time from first study treatment until progressive disease or death, assessed up to approximately 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center Hospital
Chūōku, Japan · Recruiting
Kyushu University Hospital - 300173484
Fukuoka, Japan · Recruiting
Kanazawa University Hospital
Kanazawa, Japan · Recruiting
Cancer Institute Hospital of JFCR - Dept of Orthopedic Surgery
Kōtoku, Japan · Recruiting
Nagoya University Hospital - 300176284
Nagoya, Japan · Recruiting
Okayama University Hospital - Dept of Orthopedic Surgery
Okayama, Japan · Recruiting
Osaka International Cancer Institute
Osaka, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.